This company listing is no longer active
La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Cyclacel Pharmaceuticals Gestion
Gestion contrôle des critères 2/4
We currently do not have sufficient information about the CEO.
Informations clés
Spiro Rombotis
Directeur général
US$661.0k
Rémunération totale
| Pourcentage du salaire du PDG | 84.7% |
| Durée du mandat du directeur général | 26.6yrs |
| Propriété du PDG | 2.2% |
| Durée moyenne d'occupation des postes de direction | pas de données |
| Durée moyenne du mandat des membres du conseil d'administration | 7.5yrs |
Mises à jour récentes de la gestion
Recent updates
Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Sep 30 2023 | n/a | n/a | -US$25m |
| Jun 30 2023 | n/a | n/a | -US$24m |
| Mar 31 2023 | n/a | n/a | -US$23m |
| Dec 31 2022 | US$764k | US$546k | -US$21m |
| Sep 30 2022 | n/a | n/a | -US$19m |
| Jun 30 2022 | n/a | n/a | -US$19m |
| Mar 31 2022 | n/a | n/a | -US$20m |
| Dec 31 2021 | US$1m | US$531k | -US$19m |
| Sep 30 2021 | n/a | n/a | -US$20m |
| Jun 30 2021 | n/a | n/a | -US$18m |
| Mar 31 2021 | n/a | n/a | -US$15m |
| Dec 31 2020 | US$1m | US$531k | -US$12m |
| Sep 30 2020 | n/a | n/a | -US$8m |
| Jun 30 2020 | n/a | n/a | -US$8m |
| Mar 31 2020 | n/a | n/a | -US$7m |
| Dec 31 2019 | US$1m | US$531k | -US$8m |
| Sep 30 2019 | n/a | n/a | -US$8m |
| Jun 30 2019 | n/a | n/a | -US$8m |
| Mar 31 2019 | n/a | n/a | -US$8m |
| Dec 31 2018 | US$753k | US$531k | -US$7m |
| Sep 30 2018 | n/a | n/a | -US$8m |
| Jun 30 2018 | n/a | n/a | -US$14m |
| Mar 31 2018 | n/a | n/a | -US$15m |
| Dec 31 2017 | US$776k | US$531k | -US$15m |
Rémunération vs marché: Spiro's total compensation ($USD661.05K) is above average for companies of similar size in the German market ($USD404.23K).
Rémunération et revenus: Spiro's compensation has been consistent with company performance over the past year.
PDG
Spiro Rombotis (64 yo)
26.6yrs
Titularisation
US$661,049
Compensation
Mr. Spiro George Rombotis has been President of Cyclacel Pharmaceuticals Inc. (formerly, Cyclacel Pharmaceuticals, Inc. (formerly known as Cyclacel Group plc)) since August 1997 and has been its Founding C...
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| President | 18yrs | US$661.05k | 2.19% $ 64.5k | |
| Executive VP of Finance | 18yrs | US$352.62k | 1.19% $ 35.0k | |
| Chief Medical Officer & Director | 3.3yrs | US$101.00k | 0.096% $ 2.8k | |
| Independent Director | 9.5yrs | US$116.50k | 0.32% $ 9.3k | |
| Independent Chairman | 18yrs | US$155.50k | 0.31% $ 9.1k | |
| Independent Director | 3.3yrs | US$95.49k | 0.32% $ 9.3k | |
| Member of Scientific Advisory Board | no data | pas de données | pas de données | |
| Member of Scientific Advisory Board | no data | pas de données | pas de données | |
| Member of Scientific Advisory Board | no data | pas de données | pas de données | |
| Member of Scientific Advisory Board | no data | pas de données | pas de données | |
| Independent Vice Chairman | 5.5yrs | US$130.75k | 0.31% $ 9.1k | |
| Independent Director | 1.8yrs | US$85.49k | 0.17% $ 4.9k |
7.5yrs
Durée moyenne de l'emploi
67yo
Âge moyen
Conseil d'administration expérimenté: UXI's board of directors are considered experienced (7.5 years average tenure).